SCHEMBL1415573

SCHEMBL1415573

CC(C)N(C(C)C)P(N)(=O)N(Cl)CCC#N

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL992351 0.75
SCHEMBL5366280 0.70
SCHEMBL9876709 0.68
SCHEMBL8919030 0.67 TSHR (0.31)
SCHEMBL29028507 0.67 THRB (0.30)
SCHEMBL19445479 0.67
SCHEMBL769441 0.66 TSHR (0.33)
SCHEMBL1976528 0.63
SCHEMBL3501857 0.62 TSHR (0.30)
SCHEMBL18048378 0.62 TSHR (0.30)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8323888-B2 Nanoparticles having oligonucleotides attached thereto and uses therefor NANOSPHERE, INC. (US) 2012-12-04 US disclosed
EP-1294930-B1 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR NANOSPHERE INC (US) 2011-03-30 EP disclosed
EP-1198591-B1 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR NANOSPHERE INC (US) 2011-03-16 EP disclosed
EP-1301625-B1 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR NANOSPHERE INC (US) 2010-11-03 EP disclosed
WO-2001051665-A9 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR NANOSPHERE INC. (US) 2010-09-23 WO disclosed
US-20090325812-A1 Nanoparticles having oligonucleotides attached thereto and uses therefor NANOSPHERE, INC. (US) 2009-12-31 US disclosed
EP-1198591-A4 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR NANOSPHERE INC (US) 2007-10-24 EP disclosed
US-7259252-B2 Nanoparticles having oligonucleotides attached thereto and uses therefor NANOSPHERE, INC. (US) 2007-08-21 US disclosed
US-7250499-B2 Nanoparticles having oligonucleotides attached thereto and uses therefor NANOSPHERE INC. (US) 2007-07-31 US disclosed
US-7208587-B2 Nanoparticles having oligonucleotides attached thereto and uses therefor NANOSPHERE, INC. (US) 2007-04-24 US disclosed
US-6403302-B1 DOUBLE HELICAL NUCLEIC ACID COMPRISING COMPLEMENTARY STRANDS AND OLIGONUCLEOTIDE BOUND TO TARGET SEQUENCE WITHIN; GENETIC ENGINEERING; DIAGNOSING GENE DISORDERS; ANTIPARALLEL ORIENTATION; NON-DENATURING CALIFORNIA INSTITUTE OF TECHNOLOGY 2002-06-11 US disclosed
EP-1198591-A1 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR Mirkin, Chad A. (US) 2002-04-24 EP disclosed
US-6361944-B1 Nanoparticles having oligonucleotides attached thereto and uses therefor NANOSPHERE, INC. 2002-03-26 US disclosed
WO-2002018643-A2 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR NANOSPHERE INC. (US) 2002-03-07 WO disclosed
WO-2001073123-A2 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR NANOSPHERE INC. (US) 2001-10-04 WO disclosed
WO-2001000876-A9 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR MIRKIN CHAD A (US) 2001-07-26 WO disclosed
WO-2001051665-A2 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR NANOSPHERE INC. (US) 2001-07-19 WO disclosed
US-6262241-B1 ANTISENSE COMPOUNDS WHICH CLEAVE PHOSPHORODIESTER BONDS AND IMPROVE PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES OF OLIGONUCLEOTIDES, USEFUL IN DIAGNOSING DISEASES ISIS PHARMACEUTICALS, INC. 2001-07-17 US disclosed
WO-2001000876-A1 NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO AND USES THEREFOR MIRKIN CHAD A (US) 2001-01-04 WO disclosed
EP-0320103-A2 Compounds for DNA deletion and oligomers used therefor as well as a method for use thereof AJINOMOTO CO., INC. (JP) 1989-06-14 EP disclosed